PLIANT THERAPEUTICS, INC. current report, 26 September 2023

Full document

Pliant Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

Filed September 26, 2023, under Item 8.01 (Other Events). Pliant Therapeutics announced positive safety and exploratory efficacy data from the Phase 2a INTEGRIS-PSC trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis.

Key Results and Metrics

  • The trial met its primary and secondary endpoints.
  • Bexotegrast was well tolerated during the 12-week treatment period.
  • Plasma concentrations increased with dose.
  • At the initial three doses tested, ELF scores and PRO-C3 levels declined at Week 12 versus placebo; the 160 mg dose showed statistically significant differences versus placebo.
  • Liver chemistry stabilized, with a dose-dependent trend toward reduced alkaline phosphatase levels versus placebo at Week 12.
  • Preliminary MRI results suggested improved hepatocyte function and bile flow with the 160 mg dose.
  • The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other corporate financial metrics.

Material Changes Versus Prior Comparable Period

The filing reports clinical-trial results rather than period-over-period financial results. No comparable prior-period financial data or quantified prior clinical results are provided.

Guidance, Outlook, Risks, and Unusual Items

  • The reported efficacy findings are exploratory, and the MRI findings are preliminary.
  • Results were based on a 12-week treatment period and included suspected liver fibrosis; longer-term efficacy, safety, and clinical benefit remain unestablished in this filing.
  • The filing provides no financial guidance or formal development timeline.
  • The press release describing the data is incorporated as Exhibit 99.1.

Investor Verification Items

  1. Verify the full trial population, dose cohorts, endpoint definitions, statistical methods, and magnitude of treatment effects in Exhibit 99.1.
  2. Review the detailed safety findings, including adverse events, discontinuations, and laboratory abnormalities.
  3. Confirm the numerical ELF, PRO-C3, alkaline phosphatase, and MRI results and the applicable statistical significance levels.
  4. Assess whether subsequent trials confirm the exploratory findings and establish durable clinical benefit.